Are We Ready for Expanding the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?

J Cardiovasc Pharmacol. 2024 Jul 1;84(1):26-28. doi: 10.1097/FJC.0000000000001587.

Authors

Paschalis Karakasis¹, Dimitrios Patoulias², George Giannakoulas³, Nikolaos Fragakis¹

Affiliations

¹ Second Department of Cardiology, General Hospital Hippokration, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece; and.
³ First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 38968566
DOI: 10.1097/FJC.0000000000001587

No abstract available

Publication types

Editorial

MeSH terms

Humans
Myocardial Infarction* / drug therapy
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Treatment Outcome

Substances

Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2